• Product News

Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2019 Congress

Tokyo, September 29, 2019: Eisai Co., Ltd. announced today that a series of abstracts will be presented during the European…

• Market

Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Breakthrough Therapy Designation from FDA

For LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination Treatment as Potential First-Line Treatment of Patients with Advanced Unresectable Hepatocellular Carcinoma Not…

• Latest

Sun Pharma and China Medical System Holdings enter into a License Agreement for Tildrakizumab in Greater China

Relationship gives Sun Pharma access to Greater China market for Tildrakizumab China to become a key market in future with…

• Events

Eisai to Present Data on Oncology Pipeline and Products at 55th Asco Annual Meeting

Tokyo, May 16, 2019: Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates regarding its…

Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Announce U.S. FDA Grants Breakthrough Therapy Designation for LENVIMA

In Combination with KEYTRUDA as Therapy for Previously Treated Patients with Advanced and/or Metastatic non-MSI-H/pMMR Endometrial Carcinoma Tokyo, August 05,…

MSD, Ferring complete clinical trial for Postpartum Haemorrhage

Excessive bleeding after childbirth (postpartum haemorrhage or PPH) is the leading direct cause of maternal mortality worldwide. Delhi, March 12,…